Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 22, 2013, Pages 3423-3432

  Liu, Shu Ye ^a   Zhang, Rikki Lei ^a   Kang, Hua ^a   Fan, Zhi Juan ^a   Du, Zhi ^a  

^a TIANJIN THIRD CENTRAL HOSPITAL   (China)

Author keywords

Characteristic metabolites; Hepatocellular carcinoma; Metabolomics; Potential biomarker; Ultra performance liquid chromatography mass spectrometry

Indexed keywords

CHENODEOXYCHOLIC ACID; GLYCEROPHOSPHORYLCHOLINE; HEPATITIS B SURFACE ANTIGEN; LYSOPHOSPHATIDYLCHOLINE; PHENYLALANINE; SITOSTEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84879052763     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i22.3423     Document Type: Article

References (30)

1. Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol 2012; 39: 434-439. [DOI: 10.1053/j.seminoncol.2012.05.009]
2. Zhong DN, Ning QY, Wu JZ, Zang N, Wu JL, Hu DF, Luo SY, Huang AC, Li LL, Li GJ. Comparative proteomic profles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation. Cancer Sci 2012; 103: 1833-1838.
3. Fu WM, Zhang JF, Wang H, Tan HS, Wang WM, Chen SC, Zhu X, Chan TM, Tse CM, Leung KS, Lu G, Xu HX, Kung HF. Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in Hepatocellular carcinoma and proteomic analysis. Apoptosis 2012; 17: 842-851.
4. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabo-nomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1: 153-161. [DOI: 10.1038/nrd728]
5. Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profling. Cancer Epidemiol Biomarkers Prev 2013; 22: 189-200.
6. Monteiro MS, Carvalho M, Bastos ML, Guedes de Pinho P. Metabolomics analysis for biomarker discovery: advances and challenges. Curr Med Chem 2013; 20: 257-271.
7. Davis VW, Schiller DE, Eurich D, Sawyer MB. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J Surg Oncol 2012; 10: 271. [DOI: 10.1186/1477-7819-10-271]
8. Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, Di Poto C, Wang J, Goerlitz D, Luo Y, Cheema AK, Sarhan N, Soliman H, Tadesse MG, Ziada DH, Ressom HW. LC-MS based serum metabolomics for identifcation of he-patocellular carcinoma biomarkers in Egyptian cohort. J Pro-teome Res 2012; 11: 5914-5923. [DOI: 10.1021/ pr300673x]
9. Wang X, Zhang A, Sun H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 2013; 57: 2072-2077. [DOI: 10.1002/hep.26130]
10. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X. Me-tabolomic profling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrom-etry. Anal Chim Acta 2009; 648: 98-104. [DOI: 10.1016/j.aca.2009.06.033]
11. Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, Zhao X, Wang W, Lu X, Xu Z, Wang H, Xu G. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepato-cellular carcinoma diagnosis. Mol Cell Proteomics 2012; 11: M111.010694. [DOI: 10.1074/mcp.M111. 010694]
12. Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Ka-shikura K, Ikeda S, Hirayama A, Yamamoto T, Yoshida H, Otsuka M, Tsuji S, Yatomi Y, Sakuragawa T, Watanabe H, Nihei K, Saito T, Kawata S, Suzuki H, Tomita M, Suematsu M. Serum metabolomics reveals?-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 2011; 55: 896-905. [DOI: 10.1016/j.jhep.2011.01.031]
13. Makarov A, Scigelova M. Coupling liquid chromatography to Orbitrap mass spectrometry. J Chromatogr A 2010; 1217: 3938-3945. [DOI: 10.1016/j.chroma.2010.02.022]
14. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabo-nomics. J Proteome Res 2007; 6: 469-479.
15. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Multi-and megavariate data analysis: principles and applications. Umetrics: Umea, 2001
16. Gika HG, Theodoridis GA, Wingate JE, Wilson ID. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res 2007; 6: 3291-3303. [DOI: 10.1021/ pr070183p]
17. Dunn WB, Broadhurst D, Brown M, Baker PN, Redman CW, Kenny LC, Kell DB. Metabolic profling of serum using Ultra Performance Liquid Chromatography and the LTQ-Orbitrap mass spectrometry system. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 871: 288-298. [DOI: 10.1016/j.jchromb.2008.03.021]
18. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, Lu X, Yang S, Gu J, Xu G. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009; 5: 868-876. [DOI: 10.1039/b820224a]
19. Patel M, Shariff MI, Ladep NG, Thillainayagam AV, Thomas HC, Khan SA, Taylor-Robinson SD. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract 2012; 18: 335-342. [DOI: 10.1111/j.1365-2753.2010. 01599.x]
20. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma me-tabolomics and lipid profling. Cancer Res 2011; 71: 6590-6600. [DOI: 10.1158/0008-5472.CAN-11-0885]
21. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38 Suppl 1: S136-S149.
22. Pei Y, Zhang T, Renault V, Zhang X. An overview of hepato-cellular carcinoma study by omics-based methods. Acta Bio-chim Biophys Sin (Shanghai) 2009; 41: 1-15.
23. Khwaja A, Silverman D, Sloan F, Wang Y. Are mature smokers misinformed? J Health Econ 2009; 28: 385-397. [DOI: 10.1016/j.jhealeco.2008.12.004]
24. Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR, Zhao Y, Wang J, Di Poto C, Cheema AK, Tadesse MG, Goldman R, Shetty K. Utilization of metabo-lomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 2012; 743: 90-100. [DOI: 10.1016/j.aca.2012.07.013]
25. Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, Lu X, Zhang Y, Lin X, Xu G. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 2012; 403: 203-213. [DOI: 10.1007/s00216-012-5782-4]
26. York B, Sagen JV, Tsimelzon A, Louet JF, Chopra AR, Reineke EL, Zhou S, Stevens RD, Wenner BR, Ilkayeva O, Bain JR, Xu J, Hilsenbeck SG, Newgard CB, O'Malley BW. Research resource: tissue-and pathway-specific metabolo-mic profiles of the steroid receptor coactivator (SRC) family. Mol Endocrinol 2013; 27: 366-380. [DOI: 10.1210/me.2012-1324]
27. Budczies J, Denkert C, Müller BM, Brockmöller SF, Klauschen F, Györffy B, Dietel M, Richter-Ehrenstein C, Marten U, Salek RM, Griffn JL, Hilvo M, Orešic M, Wohlgemuth G, Fiehn O. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. BMC Genomics 2012; 13: 334. [DOI: 10.1186/1471-2164-13-334]
28. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spec-troscopy in conjunction with multivariate data analysis. J Proteome Res 2007; 6: 2605-2614. [DOI: 10.1021/pr070063h]
29. Chen F, Xue J, Zhou L, Wu S, Chen Z. Identifcation of serum biomarkers of hepatocarcinoma through liquid chroma-tography/mass spectrometry-based metabonomic method. Anal Bioanal Chem 2011; 401: 1899-1904. [DOI: 10.1007/s00216-011-5245-3]
30. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011; 10: M110.004945. [DOI: 10.1074/mcp. M110.004945]